checkAd

    DGAP-News  683  0 Kommentare Novavax Announces Management Promotions


    DGAP-News: Novavax, Inc. /
    Novavax Announces Management Promotions

    19.06.2014 / 22:22

    ---------------------------------------------------------------------

    GAITHERSBURG, Md., 2014-06-19 22:22 CEST (GLOBE NEWSWIRE) --
    Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused
    on the discovery, development, and commercialization of recombinant
    nanoparticle vaccines and adjuvants, announced today a number of promotions
    within its management team.

    John A. Herrmann III, J.D. has been named Senior Vice President, General
    Counsel and Corporate Secretary. Mr. Herrmann joined Novavax in March 2010 and
    is responsible for managing all of Novavax' legal affairs, including its patent
    portfolio, transactional and contractual matters, public securities filings,
    and attending to all the duties of Corporate Secretary. Mr. Herrmann also works
    with the company's senior management team to define and develop corporate
    policies and procedures. Prior to joining Novavax, Mr. Herrmann served as
    General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic
    before it became Ore Pharmaceuticals. Prior to joining Gene Logic, Mr. Herrmann
    served as Senior Counsel for Celera Genomics and prior to that as Senior
    Corporate Counsel at Baxter Healthcare in its Renal Division. Mr. Herrmann
    received his B.A. in Political Science and History from Brown University and
    his J.D. from the University of Illinois.

    Denise Courbron, M.S., PMP has been named Vice President, Global Program
    Management to lead Novavax' program management efforts covering all vaccine
    development programs. Ms. Courbron joined Novavax in June 2010 as Executive
    Director, Global Program Management and was instrumental in Novavax' being
    awarded its $179 million influenza development contract with HHS BARDA in
    February 2011. Prior to joining Novavax, Ms. Courbron held positions of
    increasing responsibility in a number of companies in the vaccines industry,
    including PharmAthene, Intercell USA, Iomai Corporation, PPD, Baxter
    BioScience, GloboMax (ICON), and North American Vaccine. Ms. Courbron received
    a B.A. in Political Science and Spanish from Western Maryland College
    (McDaniel) and an M.S. in Biotechnology Management from the University of
    Maryland University College. Ms. Courbron is a certified Project Management
    Professional (PMP(TM)).

    'I am very pleased to announce the promotions of John and Denise. Their
    contributions over the last number of years have been critical to the success
    of the company. John has been irreplaceable assisting the management team and
    the board to navigate the regulatory, compliance, and corporate governance
    requirements of a public company. Denise's long history of experience with
    government contracts and project management has been integral to the successful
    execution of our contract with HHS BARDA. I look forward to their continued
    involvement in the success of the company,' said Stanley C. Erck, President and
    CEO.

    About Novavax

    Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
    creating novel vaccines and vaccine adjuvants to address a broad range of
    infectious diseases worldwide. Using innovative proprietary recombinant protein
    nanoparticle vaccine technology, the company produces vaccine candidates to
    efficiently and effectively respond to both known and newly emergent diseases.
    Additional information about Novavax is available on the company's website,
    novavax.com.

    CONTACT: Barclay A. PhillipsSVP, Chief Financial Officer and TreasurerNovavax,
    Inc.240-268-2000
    News Source: NASDAQ OMX


    End of Corporate News

    ---------------------------------------------------------------------

    19.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
    company of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    DGAP's Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------


    Language: English
    Company: Novavax, Inc.


    United States
    ISIN: US6700021040


    End of News DGAP News-Service
    ---------------------------------------------------------------------
    274476 19.06.2014


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Novavax Announces Management Promotions DGAP-News: Novavax, Inc. / Novavax Announces Management Promotions 19.06.2014 / 22:22 --------------------------------------------------------------------- GAITHERSBURG, Md., 2014-06-19 22:22 CEST (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a …

    Schreibe Deinen Kommentar

    Disclaimer